Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Weight and the vitamin K expoxide reductase 1 genotype primarily contribute to the warfarin dosing in pediatric patients with Kawasaki disease.

Thrombosis research - 1 Jul 2018

Wang Zhouping, Zhang Li, Huang Ping, Gu Xiaoqiong, Xie Xiaofei, Wang Yanfei, Li Wei, Zeng Qiyi

Abstract excerpt

INTRODUCTION: Warfarin therapy is recommended in children with giant coronary artery aneurysms (GCAAs) after Kawasaki disease (KD). Large individual variability makes it difficult to predict the warfarin dose. Polymorphisms in the vitamin K expoxide reductase 1 (VKORC1) and cytochrome P4502C9 (CYP2C9) genes have been reported to influence the warfarin dose. We investigated the effects of the VKORC1 and CYP2C9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Weight
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to VKORC1 gene

Share to Genotype

Share to Mucocutaneous Lymph Node Syndrome

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 29778033
DOI: 10.1016/j.thromres.2018.05.002

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Weight and the vitamin K expoxide reductase 1 genotype primarily contribute to the warfarin dosing in pediatric patients with Kawasaki disease.PMID 29778033Read ↗

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.Semantic proximity Read ↗

Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.Semantic proximity Read ↗

Genetic and clinical determinants influencing warfarin dosing in children with heart disease.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.Semantic proximity Read ↗

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.Semantic proximity Read ↗

Characterizing variability in warfarin dose requirements in children using modelling and simulation.Semantic proximity Read ↗

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.Semantic proximity Read ↗

Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Semantic proximity Read ↗

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.Semantic proximity Read ↗

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.